Description
Application
Syrosingopine has been used as a monocarboxylate transporter (MCT) inhibitor
to study its effects on anti-CD147-induced metabolon disruption in human breast cancer cells
to study its effects on Cryptosporidium parvum-infected HCT-8 cells
in orthogonal linear separation analysis (OLSA)-derived decomposed analysis
Biochem/physiol Actions
Syrosingopine is a derivative of reserpine and inhibits monocarboxylate lactate transporters 1 and 4 (MCT1/4).
Syrosingopine is an antihypertensive agent related to reserpine that was found to potentiate the anticancer effects of the antidiabetic agent metformin and phenformin without harmful effects on normal cells.
Syrosingopine is an antihypertensive agent related to reserpine that was found to potentiate the anticancer effects of the antidiabetic agent metformin and phenformin without harmful effects on normal cells. Syrosingopine was also found to potentiate the anticancer activity of mitochondrial electron transport chain (ETC) inhibitors. Its mechanism of action is currently unknown but may involve inhibition of glycolytic enzyme α-enolase rather than its known activity as an inhibitor of vesicular monoamine transporters VMAT1 and VMAT2.
